Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake
Tuesday, September 24, 2019
12:00 pm - 1:00 pm EST
The National Cancer Institute has re-issued the Funding Opportunity Announcement (FOA) Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (Clinical Trial Optional) (PAR-19-360 [R01]; PAR-19-359 [R03] and PAR-19-358 [R21]). This FOA encourages research on how the health care delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and health care delivery.
Application Due Dates:
- R01: October 17, 2019; then standard dates apply.
- R03: October 16, 2019; then standard dates apply.
- R21: October 16, 2019; then standard dates apply.
Sarah Kobrin, PhD
Chief, Health Systems and Interventions Research Branch
Healthcare Delivery Research Program
Division of Cancer Control and Population Sciences
Extramural investigators at junior, mid-, and senior levels.
This webinar will be archived on the HDRP Events webpage.